摘要
目的:比较曲普瑞林不同给药方式对子宫腺肌病患者病情控制作用的影响。方法:选择我院2011年3月—2012年1月收治的78例子宫腺肌病患者并随机分为2组,对照组38例采用常规给药方式治疗,每4周肌内注射曲普瑞林1次,观察组40例延长给药时间,每6周肌内注射曲普瑞林1次,2组疗程均为24周,比较2组患者病情控制情况。结果:治疗后2组患者的痛经评分明显优于治疗前,月经量均较治疗前明显减少,子宫内膜厚度较治疗前明显变薄,差异均有统计学意义(P<0.05),但2组间差异无统计学意义(P>0.05);治疗后2组患者的黄体生成素(LH)、卵泡刺激素(FSH)及雌二醇(E2)水平均明显降低,与治疗前比较差异均有统计学意义(P<0.05),但2组间差异无统计学意义(P>0.05);2组均无严重不良反应发生。结论:曲普瑞林不同给药方式对子宫腺肌病患者均能起到良好的病情控制作用,且安全性好,但延长给药时间可以减少用药次数及用药量,是临床首选的治疗方案。
OBJECTIVE To compare the influence of different dosage regimens of triptorelin on disease-controlling action inpatients with uterine adenomyosis. METHODS From Mar. 2011 to Jan. 2012 in our hospital, 78 patients with uterine adenomyosis were selected and randomly divided into two groups： the control group （38 cases）treated with conventional treatment,injected triptorelin once every four weeks; in the observation group （40 cases） extended the delivery time, injected triptorelinonce ery six weeks, both groups were treated for 24 weeks, the disease control situation of two groups were compared. RE-NULTS After treatment, the dysmenorrhea score of two groups were significantly better than before treatment, menstrualflow was significantly reduced and the thickness of endometrium was significantly thinner than before treatment, the differenceswere statistically significant （P〈0. 05）, but the difference was not statistically significant between two groups （P〉0. 05） ; after treatment, the luteinizing hormone （LH）, follicle-stimulating hormone （FSH） and estradiol （E2） levels of two groups were signifitantly lower, compared with before treatment, the differences were statistical significance （P〈0. （/5）, but the differencewas not statistically significant between two groups （P〉0.05） ; there were no serious adverse events. CONCLUSION Differ-ent dosage regimens of triptorelin for patients with uterine adenomyosis can play a good role in disease control and security, butextending the delivery time can reduce the number of drugs and dosage, it is the first choice of treatment program.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2013年第6期472-475,共4页
Chinese Journal of Hospital Pharmacy
